Ignite Creation Date:
2024-05-05 @ 10:41 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01165203
Status:
COMPLETED
Last Update Posted:
2018-04-30
First Post:
2010-07-15
Brief Title:
Study to Evaluate GSK Biologicals Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus HIV-Infected Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Safety and Immunogenicity of GlaxoSmithKline Biologicals Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline GSK Biologicals investigational Herpes Zoster HZ vaccine GSK1437173A in Human Immunodeficiency Virus HIV infected subjects firstly enrolling subjects treated with antiretroviral therapy ART and with high CD4 T cell counts and subsequently ART-treated subjects with low CD4 T cell counts and ART-naïve subjects with high CD4 T cell counts
This Protocol Posting has been updated following Amendment 1 of the Protocol August 2010 The impacted sections is exclusion criteria
This Protocol Posting has been updated following Amendment 1 of the Protocol August 2010 The impacted sections is exclusion criteria
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None